Financial Performance - Uni-Bio Science Group reported a revenue of HKD 353.4 million for the year ended December 31, 2021, compared to HKD 208.8 million in 2020, representing an increase of 69.2%[7]. - The gross profit for the same period was HKD 277.0 million, with a gross margin of 78.4%[7]. - The company's revenue reached a record high in 2021, showing a significant year-on-year growth of 69.3%, driven by strong sales of core products[28]. - The sales of the proprietary biological drugs, including Jinyin Peptide® and Jinyin Shu®, amounted to HKD 206.7 million, an increase of approximately 22.7% year-on-year, accounting for about 58.5% of total sales[56]. - The sales of the proprietary chemical drug, Pinap® (Voriconazole tablets), recorded significant growth, with revenue increasing from approximately HKD 37.5 million to about HKD 142.2 million due to inclusion in the national centralized procurement[53]. - The gross profit for the year was approximately HKD 277.0 million, a 53.0% increase from about HKD 181.1 million in 2020, although the gross margin decreased to 78.4% from 86.7% due to pricing discounts from centralized procurement[59]. - The company reported an operating loss of HKD 20.0 million for the year, a substantial reduction from a loss of HKD 70.9 million in 2020[49]. - The total loss narrowed to HKD 19.6 million compared to HKD 71.3 million in 2020[66]. Research and Development - Research and development expenses accounted for 14.2% of total revenue, amounting to HKD 50.2 million[7]. - The company is focusing on R&D in endocrine diseases, ophthalmology, and dermatology, with multiple patented biopharmaceuticals in various stages of development[33]. - The company has several leading patented biopharmaceuticals and high-quality generic drugs currently in different research and development phases[34]. - The second-generation Uni-PTH (pre-filled injection pen) has successfully completed clinical trials and is expected to submit a new drug application in 2022[36]. - The oral GLP-1 product under development has shown to be twice as effective as the clinical efficacy of the overseas oral GLP-1 product, semaglutide, in pharmacokinetic studies on mice[39]. - The company has initiated clinical work for the Uni-GLP-1 water injection and plans to accelerate further clinical work in 2022[37]. - The company is developing a third-generation oral Uni-PTH and collecting data for its development[36]. - The company has completed clinical trials for Uni-PTH and plans to submit a new drug application in 2022, while Uni-GLP-1's preliminary trials are expected to finish by the end of 2022[74]. Market Expansion and Strategy - Uni-Bio Science aims to enhance its operational excellence and expand its market presence in the Chinese healthcare sector[3]. - The company is committed to improving patient quality of life through innovative treatments[5]. - Uni-Bio Science is focused on becoming a leading biopharmaceutical company by introducing high-quality medical solutions to Chinese patients[3]. - The company is expanding into the medical aesthetics and functional skincare markets, with new products expected to launch within the next two years[17]. - The collaboration with Global Cosmetic aims to develop competitive new skincare raw materials[14]. - The company is optimizing production scale and efficiency for its generic drugs, particularly PinaP, to meet increasing public hospital orders[18]. - A partnership with National Pharmaceutical Group and Suzhou Yingli will enhance the supply chain and production capacity for BoShuTai[18]. - The company is exploring innovative technologies with multiple biological companies to provide alternative treatments for wet age-related macular degeneration[40]. Corporate Governance - The board consists of seven members, including three executive directors and three independent non-executive directors, ensuring a balanced governance structure[116]. - The responsibilities of the Chairman and CEO are clearly separated, enhancing accountability and independence[114]. - The audit committee consists of three independent non-executive directors and has reviewed the audited consolidated financial statements for the year ending December 31, 2021[82]. - The company has adopted the standard code of conduct for securities trading as per the listing rules, confirming compliance by all directors[84]. - The company aims to maintain and improve corporate governance quality to enhance investor confidence and support stable growth[112]. - The company has established a policy for appointing external auditors and reviewing their independence and objectivity[134]. - The board has established a process for identifying, assessing, and managing risks, ensuring continuous monitoring and reporting[156]. - The company maintains effective communication with shareholders, providing opportunities for direct interaction during the annual general meeting[161]. Production and Facilities - The company operates two GMP-certified production facilities located in Beijing and Shenzhen[6]. - A new production facility in Dongguan is set to begin construction in April 2022, aiming to enhance production efficiency and reduce costs by 2025[15]. - The new production base in Dongguan is expected to be operational by 2025, aimed at increasing production capacity and reducing costs[76]. Shareholder Information - The total number of issued shares as of December 31, 2021, is 6,349,768,147[198]. - Liang Guolong holds 1,846,832,542 shares, representing approximately 29.44% of total shares[192]. - Qiu Guorong holds 865,040,000 shares, representing approximately 13.72% of total shares[192]. - The total shares held by directors and their related entities amount to 2,740,000,000 shares[192]. - The percentage of shares held by the top five shareholders is approximately 47.85%[192]. Future Outlook - The Chinese pharmaceutical market is expected to reach USD 300.9 billion by 2025, with a compound annual growth rate (CAGR) of 12.2% driven by aging population and regulatory reforms[67]. - The global functional cosmetics market is projected to reach USD 4.1 billion by 2026, growing at a compound annual growth rate of 5.2% from USD 3.2 billion in 2021[25]. - The functional skincare market in China reached RMB 26.01 billion in 2021 and is projected to grow at a CAGR of 29.4%, reaching RMB 58.97 billion by 2023[69].
联康生物科技集团(00690) - 2021 - 年度财报